

Supp. Methods

Exome Sequencing and Analysis

All patient DNA samples were collected by local internal review board criteria, abiding by the Helsinki Treaty, and de-identified. Genomic DNA was isolated from peripheral blood samples using the Puregene Blood Kit (Qiagen; Valencia, CA). DNA quantification and quality assessment was performed using a NanoDrop spectrophotometer (Thermo Scientific; Wilmington, DE) and agarose gel electrophoresis. The Agilent SureSelect Version 4 (51Mb) exome enrichment kit was used prior to sequencing on an Illumina HiSeq 2000 instrument (Asan, et al., 2011; Bennett, 2004; Clark, et al., 2011; Parla, et al., 2011; Sulonen, et al., 2011). One hundred nucleotide long paired end reads were used to sequence each exome to an average coverage of approximately 50X before the removal of PCR duplicates.

The sequence analysis pipeline used for this study is based on the best practice variant detection guidelines developed by the Broad Institute for the Genome Analysis Tool Kit (GATK) suite of software utilities (McKenna, et al., 2010). The overall process can be described as three stages – alignment to the reference genome, identification of high-quality variations and genotypes, and annotation with biologically relevant information. Raw fastq files were quality controlled using FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>) and aligned to the human genome reference sequence (build hg19) with BWA (Li and Durbin, 2009). The SAM/BAM standard format was used to store the alignment results (Li and Durbin, 2009). GATK (McKenna, et al., 2010), Samtools (Li and Durbin, 2009), and Picard tools (<http://picard.sourceforge.net/>) were used for single nucleotide variation (SNV) and small insertion and deletion (indel) detection and quality control filtering from the SAM/BAM files. This process included the removal of duplicate reads, local re-alignment of the reads, recalibration of base quality values, identification and genotyping of single nucleotide substitutions and small insertions/deletions (GATK Unified Genotyper), and variant quality score recalibration.

Prior to gene-content and functional annotation, we identified those variants that were found at greater than 1% in the 1000 Genomes Project (2010), dbSNP (Sherry, et al., 2001) (build 135),

and the Exome Variant Server (Wassink, et al., 2001). Furthermore, all variants were also compared to our own internal database of exome sequencing results from patients without the same phenotype. Following these initial variant filtration steps, annotation of remaining variants was performed using SnpEff and SnpSift (Cingolani, et al., 2012), the dbNSFP (Liu, et al., 2011), and the Human Gene Mutation Database Professional Version (HGMD) (Stenson, et al., 2003). HGMD was used to exclude a previously known disease causing mutation. The dbNSFP database was used to provide likely variant functional consequence with annotations from SIFT (Ng and Henikoff, 2003), Polyphen2 (Adzhubei, et al., 2010), LRT (Sul, et al., 2011), MutationTaster (Schwarz, et al., 2010), conserved domain sites from InterPro (Hunter, et al., 2012), GERP scores (Cooper, et al., 2005), and SiPhy scores (Garber, et al., 2009). Variation prioritization was accomplished by three methods 1) heuristic filtering based on suspected disease inheritance, 2) likely variant functional consequence (damaging variations such as nonsense and frameshift as well as nonconservative amino acid changes in highly conserved sites receiving higher priority), and 3) a probabilistic search algorithm, VAAST (Yandell, et al., 2011). Various quality control metrics were used throughout the analysis process. Fastq files were evaluated using FastQC, mapping was evaluated using both Samtools and Qualimap (to evaluate mapping performance and evaluate coverage of target, respectively) (Garcia-Alcalde, et al., 2012; Li and Durbin, 2009), and variant quality was assessed using parallel strategies of hard filtering (thresholds used were those recommended by the GATK Best Practices) and variant quality score recalibration. We assumed that any causative variant would be transmitted in a dominant manner and exhibit near complete penetrance. VarSifter (Teer, et al., 2012) was used to perform the inheritance based, variant segregation analysis via the custom query feature. VarSifter was also used to de-prioritize those variants that failed either hard filtering criteria or variant quality score recalibration. We retained any quality controlled variants that were found in 4 out of the 7 affected family members provided that in the other 3 samples there was insufficient information to make a call and not a discordant call. Those variants that fulfilled the hypothesized inheritance model were further prioritized according to in silico predictions of pathogenicity, nucleotide conservation, and presence within a conserved protein domain. These results were then intersected with those from the VAAST algorithm. VAAST was run assuming dominant inheritance, complete penetrance, and no locus heterogeneity. The results from VarSifter and VAAST were intersected and then sorted by the VAAST probability score and

variant functional consequence scores. A quality controlled, prioritized list of genes and variants that fit our hypothesized inheritance model is available in Supp. Table S1. The highest scoring variant/gene was the chr1:236201527 G>A variant in NID1 which produces a stop codon in place of a glutamine at amino acid position 388 (Q388*). This variant (NM_002508.2 (NID1_v001): c.1162C>T, p.(Gln388*)) was found in all 14 of the affected family members in pedigree 1 by Sanger sequencing. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence. The initiation codon is codon 1.

The NID1 nonsense mutation was not found in the proband from pedigree 2. Therefore, potential NID1 interacting proteins were ascertained from several different sources and the union was used to screen all rare variants from the exome sequencing analysis of this individual. Databases used included the commercial Ingenuity Pathway Analysis (IPA) Knowledge Base (www.ingenuity.com), STRING (Szklarczyk, et al., 2011), VisAnt (Hu, et al., 2009), and GeneMania (Warde-Farley, et al., 2010), and PUBMED search for interacting proteins. Lists obtained from these databases using default settings and the gene NID1 are available as Supp. Table S1. All rare coding variants (less than 1% frequency in databases mentioned above) within these genes were identified and assess for their potential pathogenicity in the proband from pedigree 2. The list of genes and variants matching these criteria in this individual are available in Supp. Table S2. Primers and conditions used for Sanger sequencing (all with Invitrogen platinum Taq) of *NID1* and *LAMC1* exons are listed in Supp. Table S3. We discovered a novel LAMC1 variant: NM_002293.3 (LAMC1_v001): c.2237C>T, p.(Thr746Met) (nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence with the initiation codon being codon 1). This variant was submitted to the LOVD LAMC1 at https://grenada.lumc.nl/LOVD2/mendelian_genes/home.php?select_db=LAMC1

Protein Structures

We used the Yasara Structure (version 12.10.3) to generate a homology model of human LAMC1 EGF-like-6 domain (residues 722-770) using structures of other Laminin EGFLike

domains (pdb id: 1NPE, 3ZYG, 1KLO, 3TBD, 2Y38) as templates. Sequence alignment with the templates was first used to build a backbone model for aligned residues followed by loop modeling and side chain optimization using a combination of steepest descent and simulated annealing minimization. The top ranking of the 6 models generated was used as the homology model of LAMC1 EGF-like-6 domain. The above steps were automated using Yasara's hm_build macro (<http://www.yasara.org>). Another homology model was generated using the Phyre server (version 2.0) (<http://www.sbg.bio.ic.ac.uk/~phyre>), which showed agreement with the Yasara model (rmsd of 0.591 over 35 C α atoms) for the domain. PyMOL (Schrodinger, LLC) was used to visualize the homology model and to generate figures.

Supp. References

2010. A map of human genome variation from population-scale sequencing. *Nature* 467(7319):1061-73.
- Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. 2010. A method and server for predicting damaging missense mutations. *Nat Methods* 7(4):248-9.
- Asan, Xu Y, Jiang H, Tyler-Smith C, Xue Y, Jiang T, Wang J, Wu M, Liu X, Tian G and others. 2011. Comprehensive comparison of three commercial human wholeexome capture platforms. *Genome Biol* 12(9):R95.
- Bennett S. 2004. Solexa Ltd. *Pharmacogenomics* 5(4):433-8.
- Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM. 2012. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w1118; iso-2; iso-3. *Fly (Austin)* 6(2):80-92.
- Clark MJ, Chen R, Lam HY, Karczewski KJ, Chen R, Euskirchen G, Butte AJ, Snyder M. 2011. Performance comparison of exome DNA sequencing technologies. *Nat Biotechnol* 29(10):908-14.
- Cooper GM, Stone EA, Asimenos G, Green ED, Batzoglou S, Sidow A. 2005. Distribution and intensity of constraint in mammalian genomic sequence. *Genome Res* 15(7):901-13.

- Garber M, Guttman M, Clamp M, Zody MC, Friedman N, Xie X. 2009. Identifying novel constrained elements by exploiting biased substitution patterns. *Bioinformatics* 25(12):i54-62.
- Garcia-Alcalde F, Okonechnikov K, Carbonell J, Ruiz LM, Gotz S, Tarazona S, Meyer TF, Conesa A. 2012. Qualimap: evaluating next generation sequencing alignment data. *Bioinformatics*.
- Hu Z, Hung JH, Wang Y, Chang YC, Huang CL, Huyck M, DeLisi C. 2009. VisANT 3.5: multi-scale network visualization, analysis and inference based on the gene ontology. *Nucleic Acids Res* 37(Web Server issue):W115-21.
- Hunter S, Jones P, Mitchell A, Apweiler R, Attwood TK, Bateman A, Bernard T, Binns D, Bork P, Burge S and others. 2012. InterPro in 2011: new developments in the family and domain prediction database. *Nucleic Acids Res* 40(Database issue):D306-12.
- Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25(14):1754-60.
- Liu X, Jian X, Boerwinkle E. 2011. dbNSFP: a lightweight database of human nonsynonymous SNPs and their functional predictions. *Hum Mutat* 32(8):894-9.
- McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M and others. 2010. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 20(9):1297-303.
- Ng PC, Henikoff S. 2003. SIFT: Predicting amino acid changes that affect protein function. *Nucleic Acids Res* 31(13):3812-4.
- Parla JS, Iossifov I, Grabill I, Spector MS, Kramer M, McCombie WR. 2011. A comparative analysis of exome capture. *Genome Biol* 12(9):R97.
- Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. 2010. MutationTaster evaluates disease-causing potential of sequence alterations. *Nat Methods* 7(8):575-6.
- Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. 2001. dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res* 29(1):308-11.
- Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeyasinghe S, Krawczak M, Cooper DN. 2003. Human Gene Mutation Database (HGMD): 2003 update. *Hum Mutat* 21(6):577-81.

- Sul JH, Han B, Eskin E. 2011. Increasing power of groupwise association test with likelihood ratio test. *J Comput Biol* 18(11):1611-24.
- Sulonen AM, Ellonen P, Almusa H, Lepisto M, Eldfors S, Hannula S, Miettinen T, Tyynismaa H, Salo P, Heckman C and others. 2011. Comparison of solution-based exome capture methods for next generation sequencing. *Genome Biol* 12(9):R94.
- Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguéz P, Doerks T, Stark M, Muller J, Bork P and others. 2011. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. *Nucleic Acids Res* 39(Database issue):D561-8.
- Teer JK, Green ED, Mullikin JC, Biesecker LG. 2012. VarSifter: visualizing and analyzing exome-scale sequence variation data on a desktop computer. *Bioinformatics* 28(4):599-600.
- Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT and others. 2010. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. *Nucleic Acids Res* 38(Web Server issue):W214-20.
- Wassink TH, Piven J, Patil SR. 2001. Chromosomal abnormalities in a clinic sample of individuals with autistic disorder. *Psychiatr Genet* 11(2):57-63.
- Yandell M, Huff C, Hu H, Singleton M, Moore B, Xing J, Jorde LB, Reese MG. 2011. A probabilistic disease-gene finder for personal genomes. *Genome Res* 21(9):1529-42.

Supplementary Table 1: Potential NID1 Interacting Partners

Database Queried	IPA		STRING	VisAnt	GeneMania	PUBMED PATHWAY	PUBMED CO-EXPRESSION
Genes	AHR	LACRT	CLIC1	HSPG2	NID1	COL3A1	FOXC1
	BMI1	LAMA1	PLXDC1	PRELP	HSPG2	COL6A1	PLXCD1
	CHUK	LAMC1	NID1	MDK	LAMC1	COL4A1	ZIC
	COL18A1	LAMC2	HSPG2	FBLN2	COL4A1	COL4A2	ZIC2
	COL1A1	LAMC3	COL4A1	FBLN1	COL4A2	NID2	ZIC3
	COL4A1	Laminin	PLAU	LAMA1	PLXDC1	SPARC	ZIC4
	COL4A2	Laminin1	FBLN2	SKIL	NID2	KDR	
	ELN	LGALS3BP	FBLN1	COL1A1	FBLN2	HSPG2	
	ERBB2	MDK	FN1	LGALS3BP	ENPEP		
	ERBB3	MMP1		COL13A1	COL3A1		
	ERBB4	MMP12		FGB	LRRC17		
	FBLN1	MMP14		FGA	COL18A1		
	FBLN2	MMP2		LAMC2	LACRT		
	FGA	MMP3		LAMC1	LAMC2		
	FGF	MMP7		COL4A1	COL6A3		
	Fibrinogen	NFKBIA		APP	SPARC		
	FN1	NID1		LACRT	CALD1		
	HRAS	NID2		PTPRF	SERPINH1		
	HSPG2	PLXDC1		PLAU	LAMB1		
	IKBKB	PTPRF		PLXDC1	FBLN1		
	IKBKG	RHO		ITGAV	PDGFRB		
	IL13	SERPING1		NID1			
	ITGA3	SKIL		ITGB3			
	ITGB1	TNF					

Supplementary Table 2: Rare Coding Variants within Genes that Encode Proteins Predicted to be NID1 Interacting Partners

Chr	LeftFlank	RightFlank	Gene_name	type	muttype	ref_allele	var_allele
chr3	13613080	13613082	FBLN2	DOWNSTREAM;NON_SYNONYMOUS_CODING	SNP	C	T
chr1	22167603	22167605	HSPG2	UPSTREAM;NON_SYNONYMOUS_CODING	SNP	G	C
chr18	6956510	6956512	LAMA1	UPSTREAM;NON_SYNONYMOUS_CODING	SNP	C	T
chr9	133962979	133962981	LAMC3	NON_SYNONYMOUS_CODING	SNP	C	T
chr1	183091221	183091223	LAMC1	UPSTREAM;NON_SYNONYMOUS_CODING	SNP	C	T
chr18	7033037	7033039	LAMA1	NON_SYNONYMOUS_CODING	SNP	G	A
chr22	45944567	45944569	FBLN1	NON_SYNONYMOUS_CODING	SNP	A	G

Supplementary Table 3: <i>NID1</i> and <i>LAMC1</i> PCR primers and annealing Temperatures			
NID1	direction	primer sequence	annealing Temp
Exon 1	Forward	GTTACATCCCCGCCTTCCT	60°C
	Reverse	CCTGCTACGCCCAAGTCC	
Exon 2	Forward	AGCATGGGTACAGCTGACAGT	60°C
	Reverse	CACAAGGCGTGAGACCAAAG	
Exon 3	Forward	TGAGAATATTGCCATCGCTCT	60°C
	Reverse	TGCAAAACTTAAATCCATAGGAA	
Exon 4	Forward	TTGCAGACCAACACAGATCC	60°C
	Reverse	AACTGACATCTCCCCAGCAG	
Exon 5	Forward	AGTGCTTGAGGGTGCCTAGA	60°C
	Reverse	TGTGGGTAAAGCAACATGGA	
Exon 6	Forward	GACCCAGTGCTGTTTTGTT	60°C
	Reverse	GAGTTCTCCTTCCATCCATCC	
Exon 7	Forward	ACCAACCCCACTCCACACT	58°C
	Reverse	CTCCAGATCCCAGAGACAGC	
Exon 8	Forward	TTATGGGCAGGGAATACCAC	60°C
	Reverse	TTTTTCCTGCCAGAAGATACTTT	
Exon 9	Forward	AGTTGTGGTTGACTTTCTGTGG	60°C
	Reverse	GGTTTACAGAACGTGGATGC	
Exon 10	Forward	GCAAGACTCCATCTCGGAAA	60°C
	Reverse	CAGCACCTTCCAACTTGACC	
Exon 11	Forward	TCCAGGCATGGTCTCTCTTT	60°C
	Reverse	TGAGTTGGTGATTGGCACAT	
Exon 12	Forward	TTTGAGTAAGTGGCTTAAATTATTGG	60°C
	Reverse	ATGGACAGGGCAGGCAAT	
Exon 13	Forward	TGATGAAACAAAACCCAGTGA	60°C
	Reverse	GGTCCAGCAGAAGAGCAAAG	
Exon 14	Forward	ACCTGATGTGTGGGTGTGTG	60°C
	Reverse	CCTGGGGTTCTGGTCTGATA	
Exon 15	Forward	CAAAAGATATCCAAATGCCTGT	60°C
	Reverse	TTTGGCTTCATTTGCTGTTC	
Exon 16	Forward	GGATTGGACACCATGTGAAA	60°C
	Reverse	CAGGAGACCAATGCTGGAGT	
Exon 17	Forward	TGTTTTCATGTCTGCCAATCA	60°C
	Reverse	CAGGTGGCTGGTTAGATTTG	
Exon 18	Forward	CCACTCTTGCCCTCATTACTC	58°C
	Reverse	AGAGGCCAGATGGGAAGG	
Exon 19	Forward	TGGCCTCCAGTTTATCCTCA	60°C
	Reverse	CATACGGGTAGCAGCCAGAG	
Exon 20	Forward	CACACAAGAAGGAGCCCACT	60°C
	Reverse	CAGCCAGAGGACACTTTTCA	

LamC1	direction	primer sequence	annealing Temp
Exon1A	Forward	CAGGCTCAAGCAGCGAAG	56°C
Exon1A	Reverse	CGTCGCACAGGTGACAGG	
Exon1B	Forward	ATGCCCCGAGTTCGTCAAC	58°C
Exon1B	Reverse	GCTGGCGAGCAGTAGCAG	
Exon2	Forward	CCAAATAAGCTGGGAATAGAGG	58°C
Exon2	Reverse	GCTCTCTGTCTGTGTGCTCA	
Exon3	Forward	GTGCTAAAGAGGGCGTAAGTT	58°C
Exon3	Reverse	TGCAAAAGCTCCAAACACTTT	
Exon4	Forward	GGACTTTGCAGCTGTTCCAT	58°C
Exon4	Reverse	GGCCTTTCAGAGCTTTCCTT	
Exon5	Forward	TCTGTCTCAGAGATGTGGGAAAT	58°C
Exon5	Reverse	GTCCAAATGCCTTGAAACA	
Exon6	Forward	GGCCGAATTTTTGTTTGAACA	58°C
Exon6	Reverse	TTACCCTGCTGCCAATAAGC	
Exon7	Forward	TGTAACAAGGGCTGACTTG	60°C
Exon7	Reverse	TTGAAATATGGTAACAGAAAACACA	
Exon8	Forward	TGTCGAAGGCTTCAATTGTG	58°C
Exon8	Reverse	CAAAAAGCCCTCAAAGAGTCA	
Exon9	Forward	TTTTTATGATACATAGAGGACCTGAA	58°C
Exon9	Reverse	TGGCAAGAATGTGAGACTG	
Exon10	Forward	CAGTCTGACCTGCTGTGTGC	58°C
Exon10	Reverse	CACCACAATAACCCAGAAGTTTT	
Exon11	Forward	TCCAGAATTGTCTTACAGAGG	58°C
Exon11	Reverse	GGAAAGAGAACTTTTGCATTATCA	
Exon12	Forward	TCTGGAATTTGGGTCTAGTT	56°C
Exon12	Reverse	AAGACAATGAGCACTTCTACACAA	
Exon13	Forward	ATATACTTGTACATTTGCCTGTTTTC	58°C
Exon13	Reverse	CCCCTTCCCCTAGGTCTTT	
Exon14	Forward	CCAGTGGTAATCTAGCACCAA	58°C
Exon14	Reverse	AAGAGACACACAAGAATTCTCACAA	
Exon15	Forward	CAGTACCAACCTGGCAAC	58°C
Exon15	Reverse	GCAAAGATTACTTTCACCAAAGG	
Exon16	Forward	CCATTCAGTTTTCTGATACAAGTTACA	58°C
Exon16	Reverse	GGCTAGACTGAGGCTGTCAAA	
Exon17	Forward	TCTCTGCTAAACAGACTTAGCCATT	56°C
Exon17	Reverse	CAGTAAGTTGCCACTCAACGTC	
Exon18	Forward	TGTGTGTCCTACCTTCCCTTT	58°C
Exon18	Reverse	TGGTCCATCTCACAGAAGTCA	
Exon19	Forward	TGAGATGATATGATCCTCTTCAGAT	58°C
Exon19	Reverse	CATCCCCACCTCAGACGTT	
Exon20	Forward	AATGTAAATAATTCAGTCCTTTGAGAA	56°C
Exon20	Reverse	ACCCATAACAGAAGCCACA	
Exon21	Forward	CCTGAATTTTACTTATGTCCCTATCA	58°C
Exon21	Reverse	AGGGGTGTAAACCACTTTCAA	
Exon22	Forward	TGCTAAAAGCAGCTAAGATTGTCA	58°C
Exon22	Reverse	ATAGACTTGGGGGAGAGACG	
Exon23	Forward	TGCAGTTCTTTTAAAAATATCATTGAG	58°C
Exon23	Reverse	CTCAAGAAATGAAGCGACCTG	
Exon24	Forward	GAGCCTGTCTGTCCAGGAG	58°C
Exon24	Reverse	CACTCTAGTGGCGGAAGCAT	
Exon25	Forward	ACCCTGACTTCCATTGTTCA	56°C
Exon25	Reverse	GCTCTGAGGGTCTGAAAGA	
Exon26	Forward	AGCGGGAGCATACTTGAGAA	56°C
Exon26	Reverse	TCAACAAGTGGGGGATCTTT	
Exon27	Forward	TTAGATTTGTTGGGTCATTGG	58°C
Exon27	Reverse	CAAAAGATTTCAGAGACTGACAAAAA	
Exon28	Forward	CAGGTAATTGTGAAGGGATCATT	58°C
Exon28	Reverse	ACTCTGTGGCCTCACAACCTG	